Mylan Pharmaceuticals, a subsidiary of global pharmaceutical company Mylan, has launched Fenofibrate Capsules USP, 43 mg and 130 mg.
Fenofibrate Capsules, which are generic equivalent to Lupin Atlantis Holdings’ Antara Capsules, are indicated as an adjunct to diet to reduce elevated LDL-C, Total-C and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia.
In addition, Fenofibrate Capsules reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Fenofibrate has not been shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus, according to Mylan,
According to IMS Health, Mylan currently has 184 ANDAs pending FDA approval representing $80.7bn in annual sales, out of which 36 pending ANDAs are potential first-to-file opportunities, representing $21.1bn in annual brand sales, for the 12 months ending 30 June 2012.